Abstract:Non-small cell lung cancer (NSCLC) is the leading cause of cancer related deaths in the United States and worldwide. Receptor tyrosine kinase (RTK) signaling through Epidermal Growth Factor Receptor (EGFR) has been shown to play a key role in the development and progression of NSCLC. Two activating mutations within EGFR, L858R and del19, have been demonstrated to lead to oncogene addiction and have also been shown to confer sensitivity to targeted EGFR inhibitors (e.g. erlotinib and gefitinib). Earlier work has demonstrated a crucial role for the EGFR downstream effector c-Src in the upregulation of Vascular Endothelial Growth Factor (VEGF), a HIF-1\#945; regulated gene. We have identified a correlation between mutant EGFR and elevated HIF-1\#945; protein levels. Thus, we hypothesized that c-Src may be a critical downstream effector of mutant EGFR and may have a central role in the upregulation of HIF-1\#945; signaling by activated EGFR. NSCLC cell lines were treated with erlotinib to demonstrate a role for mutant EGFR in the upregulation of HIF-1\#945; and subsequently VEGF protein levels. HCC827 NSCLC cells, expressing the EGFR sensitizing mutant, had significantly reduced HIF-1\#945; protein levels and VEGF secretion when treated with the EGFR inhibitor, whereas, A549 cells, expressing the wild-type EGFR, were minimally effected by erlotinib treatment, compared their respective untreated controls. Furthermore, transient transfection with del19 EGFR led to increased VEGF promoter activity as demonstrated by a luciferase assay. These data demonstrate a central role for mutant EGFR signaling in the upregulation of HIF-1\#945; protein levels and VEGF secretion. Hence, signaling through mutant EGFR uncouples the normal regulation of HIF-1\#945; from hypoxia leading to aberrant expression of the angiogenic growth factor, VEGF. To identify critical signaling pathways potentially involved in the EGFR-induced up-regulation of HIF-1\#945;, multiple inhibitors were utilized. Inhibition of Mek did not affect HIF-1\#945; protein levels compared to controls, whereas inhibition of phosphotidylinositol-3-kinase (PI3K) led to a 50% reduction in HIF-1\#945; protein levels versus untreated cells. The Src family inhibitor PP2 led to a complete reduction of HIF-1\#945; protein, and similar results were seen with erlotinib. Moreover, erlotinib and PP2 led to a partial reduction of HIF-2\#945; protein levels. Collectively, our data demonstrate that NSCLC cells expressing activating mutations in EGFR have elevated HIF-1\#945; protein levels and that the c-Src signaling pathway may play a central role in the uncoupling of HIF-1\#945; signaling from hypoxia-induced regulation. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4216.

A Novel Egfr Isoform Confers Increased Invasiveness To Cancer Cells

Data from A Novel EGFR Isoform Confers Increased Invasiveness to Cancer Cells

Supplementary Methods, Figures 1 - 6, Tables 1 - 4 from A Novel EGFR Isoform Confers Increased Invasiveness to Cancer Cells

Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.

A Promising New Cancer Marker: Long Noncoding RNA EGFR-AS1

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR

Effect of novel epidermal growth factor receptor isoform EGFRvA on migration of human glioma U87MG cells and its possible mechanism

Egf Potentiated Oncogenesis Requires A Tissue Transglutaminase-Dependent Signaling Pathway Leading To Src Activation

Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells.

Abstract A033: Nuclear EGFR as a regulator of the tumor microenvironment

[Tumor Biotherapy Based on Epidermal Growth Factor Receptor As a Target].

Egfrviii Mediates Hepatocellular Carcinoma Cell Invasion By Promoting S100 Calcium Binding Protein A11 Expression

Epidermal Growth Factor Receptor Emerges as a Viable Target for Reducing Tumorigenicity of MDCK Cells

EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation

Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion Via the EGFR/GSK-3β/Foxp3 Axis

Human EVI2B Acts As a Janus-faced Oncogene/antioncogene by Differently Affecting As Per Cancer Type Neoplastic Cells Growth and Immune Infiltration

High Expression of EGFR Predicts Poor Survival in Patients with Resected T3 Stage Gastric Adenocarcinoma and Promotes Cancer Cell Survival

Aberrant Epidermal Growth Factor Receptor Signaling And Enhanced Sensitivity To Egfr Inhibitors In Lung Cancer

Endocrine gland‑derived vascular endothelial growth factor modulates proliferation, apoptosis and migration in pancreatic cancer cells.

Abstract #4216: A Role for C-Src in EGFR-induced Upregulation of HIF-1\#945;